The company's CTPIC technology platform uses a non-viral vector to target cancer cells that over-express certain receptors, driving a combination of apoptosis and modulation of the innate and adaptive immune cells. TargImmune's therapeutics are the first in a new class known as Targeted Apoptotic Immune Modulators (TAIMs), and their unique viral mimicry approach has the potential to transform outcomes for cancer patients. Founded in 2016, TargImmune Therapeutics is a biotechnology venture capital firm headquartered in Basel, Switzerland, seeking to invest in the healthcare sector.